A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

NCT01870895 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

577

Enrollment

INDUSTRY

Sponsor class

Conditions

Diarrhea-predominant Irritable Bowel Syndrome

Interventions

DRUG: YM060
DRUG: Placebo

Sponsor

Astellas Pharma Inc